Shire’s partner in Japan, Shionogi & Co has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv, a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD), a common psychiatric disorder in children and adolescents.
Intuniv is a selective alpha-2A adrenergic receptor agonist. With a unique mechanism of action, Intuniv represents an additional treatment option in the management of ADHD, the company said in its press release.
ADHD causes inattention, hyperactivity or impulsivity, or a combination of these symptoms and can have substantial impact on all major areas of life, including: schooling, work and employment, behaviour, social functioning, self-esteem and health.